Chris Freeman Sells 24,406 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) insider Chris Freeman sold 24,406 shares of Guardant Health stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $118.67, for a total transaction of $2,896,260.02. Following the sale, the insider owned 60,034 shares of the company’s stock, valued at approximately $7,124,234.78. The trade was a 28.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Guardant Health Stock Performance

NASDAQ:GH traded up $0.90 during mid-day trading on Tuesday, hitting $119.85. 1,982,319 shares of the company’s stock traded hands, compared to its average volume of 2,091,200. The firm’s 50 day simple moving average is $91.85 and its 200 day simple moving average is $99.08. Guardant Health, Inc. has a 1 year low of $37.73 and a 1 year high of $121.01. The company has a market cap of $15.89 billion, a PE ratio of -35.35 and a beta of 1.48.

Hedge Funds Weigh In On Guardant Health

Several large investors have recently modified their holdings of GH. BankChampaign National Association bought a new stake in Guardant Health during the first quarter valued at $809,000. Western Wealth Management LLC acquired a new stake in shares of Guardant Health during the first quarter worth $125,000. Hamilton Wealth LLC raised its holdings in shares of Guardant Health by 103.0% during the first quarter. Hamilton Wealth LLC now owns 76,700 shares of the company’s stock worth $7,085,000 after purchasing an additional 38,916 shares during the period. Edgestream Partners L.P. lifted its position in shares of Guardant Health by 321.6% in the 1st quarter. Edgestream Partners L.P. now owns 32,257 shares of the company’s stock worth $2,980,000 after buying an additional 24,606 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in shares of Guardant Health by 19.4% in the 1st quarter. Janus Henderson Group PLC now owns 140,345 shares of the company’s stock valued at $12,960,000 after buying an additional 22,844 shares during the period. Institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on GH. UBS Group reaffirmed a “buy” rating and set a $175.00 price target on shares of Guardant Health in a research report on Friday, January 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. Stifel Nicolaus lifted their target price on shares of Guardant Health from $120.00 to $130.00 and gave the company a “buy” rating in a report on Friday, February 20th. Evercore set a $110.00 price target on shares of Guardant Health in a research report on Friday, February 20th. Finally, TD Cowen reiterated a “buy” rating on shares of Guardant Health in a report on Thursday, May 21st. Nineteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $129.53.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.